Emergent Biosolutions Net Income

Emergent Biosolutions (EBS) currently reports a net income of $-270M as of September 2026. That compares with $76M in the prior-year period — down 452.4% year over year. That is below the Healthcare sector average of $1.5T. Use the charts on this page to explore Emergent Biosolutions's net income history and peer comparisons.

Emergent Biosolutions's net income decreased from $76M to $-270M — a 452.4% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Emergent Biosolutions's net income of $-270M is lower than the Healthcare sector average of $1.5T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Emergent Biosolutions reported $-270M in net income as of September 2026. That compares with $76M in the prior-year period — down 452.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-270M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.5T. From there, open related valuation or income-statement pages for Emergent Biosolutions, and consider following EBS for alerts when major investors trade the stock.